Last reviewed · How we verify
Hawaii Pacific Health — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| ranibizumab intravitreal injection | ranibizumab intravitreal injection | phase 3 | anti-VEGF agent | VEGF-A | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Jaeb Center for Health Research · 1 shared drug class
- Moorfields Eye Hospital NHS Foundation Trust · 1 shared drug class
- Novartis · 1 shared drug class
- ONL Therapeutics · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Hawaii Pacific Health:
- Hawaii Pacific Health pipeline updates — RSS
- Hawaii Pacific Health pipeline updates — Atom
- Hawaii Pacific Health pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Hawaii Pacific Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hawaii-pacific-health. Accessed 2026-05-17.